PR Newswire
LONDON, March 9, 2026
LONDON, March 9, 2026 /PRNewswire/ — The «Cell and Gene Therapy Manufacturing Market – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032» report has been added to the Credence Research Inc. offering.
https://mma.prnewswire.com/media/2562161/Credence_Research_Logo.jpg
The global Cell and Gene Therapy Manufacturing Market is projected to grow from USD 19.3 Billion in 2024 to an estimated USD 146.2 Billion by 2032, registering a strong CAGR of 28.80% during the forecast period. This exceptional expansion reflects rising demand for advanced therapeutic platforms, increasing commercialization of gene and cell therapies, and continued innovation in automated, scalable, and quality-driven manufacturing processes across the biotechnology and pharmaceutical industries.
Scope & Segmentation – Cell and Gene Therapy Manufacturing Market
The report provides a comprehensive analysis of the global Cell and Gene Therapy Manufacturing Market, covering revenue forecasts from 2024 to 2032. It evaluates market drivers, trends, challenges, opportunities, competitive landscape, and regional dynamics shaping the development and commercialization of advanced therapies. The study examines manufacturing scale-up, automation, regulatory environments, viral vector production, workflow optimization, and the role of personalized medicine in driving long-term industry growth.
The report also assesses increasing investment in advanced manufacturing infrastructure, the shift toward commercial-scale production, and the expanding role of contract development and manufacturing partners in supporting the market. It highlights how process development, fill-finish, analytical testing, vector production, and raw material quality are becoming more critical as the industry transitions from early clinical programs to broader commercialization.
The cell and gene therapy manufacturing market is segmented based on type, scale, mode, work flow, and geography.
- By Type, the market includes Cell Therapy Manufacturing and Gene Therapy Manufacturing.
- By Scale, the market includes Pre-commercial/R&D Scale Manufacturing and Commercial Scale Manufacturing.
- By Mode, the market includes Contract Manufacturing and In-house Manufacturing.
- By Work Flow, the market includes Cell Processing, Cell Banking, Process Development, Fill & Finish Operations, Analytical and Quality Testing, Raw Material Testing, Vector Production, and Others.
- By Geography, the market is analyzed across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, with country-level coverage for the U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, China, Japan, India, South Korea, Southeast Asia, Brazil, Argentina, GCC Countries, and South Africa.
Request your sample report today & start making informed decisions powered by Credence Research Inc.! – https://www.credenceresearch.com/report/cell-and-gene-therapy-manufacturing-market
Why This Report Matters
- This report provides a detailed view of one of the fastest-growing segments in advanced biomanufacturing, with the market projected to expand from USD 19.3 billion in 2024 to USD 146.2 billion by 2032.
- It helps decision-makers assess how automation, viral vector innovation, personalized medicine, and commercial-scale manufacturing are reshaping the cell and gene therapy production ecosystem.
- The study offers regional intelligence across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, helping companies prioritize expansion, outsourcing, and infrastructure investment strategies.
- For CXOs, investors, CDMOs, biotech innovators, and pharmaceutical manufacturers, this report delivers actionable intelligence to support manufacturing scale-up, partnership strategy, regulatory planning, and long-term growth.
Market Overview:
- Industry Landscape and Value Chain Assessment
- Supply-Side Evaluation
- Demand-Side Evaluation
- Stakeholder Mapping
- Porter’s Five Forces Review
- PESTLE Environment Assessment
- Market Forecast and Future Direction
- Short-Term Forecast (0-2 Years)
- Mid-Term Forecast (3-5 Years)
- Long-Term Forecast (5-10 Years)
- Market Entry and Expansion Strategy
Market Insights:
- Customer and End-User Analysis
- Customer Experience Comparison
- Growth Opportunity Assessment
- Channel and Distribution Review
- Pricing Movement Analysis
- Regulatory and Compliance Review
- Sustainability and ESG Assessment
- Risk and Disruption Analysis
- Investment Return and Cost Evaluation
Key Attributes
Attribute
Details
Market Size 2024
USD 19,305.00 Million
Market Size 2032
USD 146,216.60 Million
CAGR (2025-2032) 28.80 %
Forecast Period
2025-2032
Base Year 2024
Historical Period
2020-2023
Segmentation Covered
Type, Scale, Mode, Work Flow, Geography
Key Regions
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Major Players F. Hoffmann-La Roche Ltd., Catalent Inc., Samsung Biologics, Boehringer Ingelheim,
Miltenyi Biotec, Merck KGaA
Regional Growth Reflects Biotech Infrastructure, Regulatory Support, and Research Expansion
North America holds the largest share of the global Cell and Gene Therapy Manufacturing Market, accounting for approximately 45% of global revenue. The region benefits from significant R&D investments, a strong biotechnology ecosystem, advanced healthcare infrastructure, and supportive regulatory mechanisms such as accelerated approval pathways. The U.S. remains the key contributor, supported by major pharmaceutical and biotech players and well-established academic research networks.
Europe represents approximately 30% of the global market and stands as the second-largest regional segment. Countries including Germany, the U.K., and France are leading market expansion, supported by favorable EMA frameworks, strong biotechnology research activity, and increasing partnerships between biotechnology companies and contract manufacturing organizations.
Asia Pacific is expected to witness substantial growth over the forecast period, driven by growing government support for gene therapy, increasing healthcare access, rising investments in biotechnology research, and expanding regional manufacturing capabilities. The region is becoming increasingly attractive for both therapy development and localized production infrastructure.
Latin America and Middle East & Africa are also gradually gaining traction as healthcare systems strengthen and awareness of advanced therapies rises. While these regions currently account for smaller shares, long-term opportunities are supported by increasing healthcare modernization efforts and improving access to specialized treatments.
Market Challenges Include High Production Costs, Regulatory Complexity, and Supply Chain Constraints
One of the major constraints in the cell and gene therapy manufacturing market is the high cost of production. These therapies require specialized facilities, advanced equipment, highly skilled labor, and rigorous quality controls, especially for patient-specific or small-batch therapeutic programs. This creates substantial cost pressure and limits scalability.
The market also faces ongoing regulatory hurdles, as manufacturers must navigate complex approval pathways involving extensive clinical evidence, process validation, and long-term product monitoring. Regulatory compliance is resource-intensive and can delay commercialization.
In addition, the specialized and fragmented supply chain for viral vectors, raw materials, and cell lines presents a significant operational challenge. Ensuring continuity, quality consistency, and logistics coordination across stakeholders is essential but difficult, particularly as global demand accelerates.
Future Outlook
The Cell and Gene Therapy Manufacturing Market is expected to witness sustained rapid expansion through 2032, driven by increasing investment in automated manufacturing technologies, expanding commercial demand, and rising adoption of personalized therapeutic approaches. Manufacturers are expected to continue prioritizing scalable and cost-efficient production models that improve consistency and reduce turnaround times.
Viral vector production capacity, AI-enabled process control, robotic cell handling, and localized manufacturing hubs will play an increasingly central role in the market’s next phase of growth. As regulatory clarity improves and more advanced therapies gain acceptance, companies that combine innovation, compliance readiness, and scalable manufacturing expertise will be best positioned to lead the market.
Competitive Landscape
The global Cell and Gene Therapy Manufacturing Market is highly competitive, with leading participants focusing on advanced manufacturing technologies, strategic alliances, facility expansion, and end-to-end service capabilities. Major companies such as F. Hoffmann-La Roche Ltd., Catalent Inc., and Samsung Biologics are strengthening their positions through robust R&D capabilities and diversified manufacturing offerings.
Other key players including Boehringer Ingelheim, Miltenyi Biotec, and Merck KGaA are contributing to the competitive environment through specialization in viral vector production, gene editing technologies, and cell therapy manufacturing support. Strategic partnerships, outsourcing models, and capacity expansion remain central to competitive differentiation across the market.
Key Players
- Hoffmann-La Roche Ltd.
- Catalent Inc.
- Samsung Biologics
- Boehringer Ingelheim
- Miltenyi Biotec
- Merck KGaA
Recent Industry Developments
In February 2026, Johnson & Johnson announced an investment of more than USD 1 billion to build a next-generation cell therapy manufacturing facility in Pennsylvania focused on personalized cell therapies, including treatments targeting multiple myeloma.
In February 2026, Cellipont Bioservices and Soter Bio announced a strategic collaboration to offer integrated U.S.-based manufacturing for complex cell therapy programs requiring coordinated biomolecule and cellular processing.
Report Coverage
The research report offers an in-depth analysis based on Type, Scale, Mode, Work Flow, and Region. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, and the primary drivers and constraints shaping industry performance.
The report also examines market dynamics, regulatory scenarios, technological developments, and the broader economic factors influencing industry expansion. It further provides strategic recommendations for both new entrants and established companies looking to navigate the operational and regulatory complexity of the cell and gene therapy manufacturing ecosystem.
Download Sample –
Related Reports –
Allogeneic Human Chondrocyte Market https://www.credenceresearch.com/report/allogeneic-human-chondrocyte-marketTissue Regeneration Scaffold Market https://www.credenceresearch.com/report/tissue-regeneration-scaffold-marketPreimplantation Genetic Testing Market https://www.credenceresearch.com/report/preimplantation-genetic-testing-marketListeria Monocytogenes Infections Treatment Market https://www.credenceresearch.com/report/listeria-monocytogenes-infections-treatment-marketDegenerative Disc Disease Market https://www.credenceresearch.com/report/degenerative-disc-disease-pipeline-insightsPrenatal and Newborn Genetic Testing Market https://www.credenceresearch.com/report/prenatal-and-newborn-genetic-testing-marketCloning and Mutagenesis Market https://www.credenceresearch.com/report/cloning-and-mutagenesis-marketElectrolysis Captive Hydrogen Generation Market https://www.credenceresearch.com/report/electrolysis-captive-hydrogen-generation-marketChemical Merchant Hydrogen Generation Market https://www.credenceresearch.com/report/chemical-merchant-hydrogen-generation-marketAndrogenetic Alopecia Treatment Market https://www.credenceresearch.com/report/androgenetic-alopecia-treatment-market
About Us
Credence Research Inc is a global market intelligence and consulting firm founded in 2015. It delivers deep market insights, quantitative analysis, and strategic guidance to business leaders, investors, governments, NGOs, and non-profit groups worldwide. The company helps organizations evaluate markets, understand trends, reduce risk, and make data-driven decisions that support growth and competitive strategy. Credence Research is known for rigorous research methods and comprehensive analytics.
The firm produces detailed reports covering market size, forecasts, growth drivers, trends, and competitive landscapes across many industries. Each report often includes frameworks like PESTLE and Porter’s Five Forces to give a complete view of market dynamics and future potential. Credence Research also provides tailored consulting services, due diligence support, go-to-market planning, and pre-IPO research to strengthen client strategies and investment narratives. Its insights come from both primary and secondary research, expert interviews, and advanced data modelling. The firm’s client base spans Europe, the Americas, Asia-Pacific, and the Middle East/Africa.
To find out more, visit www.credenceresearch.com or follow us on X.com, LinkedIn and Facebook
Contact Us -Credence Research Inc,Tower C-1105, S 25,Akash Tower,Vishal Nagar,Pimple Nilakh, Haveli,Pune – 411027, IndiaUSA: +1-888-600-6441Email: [email protected] Our Website: https://www.credenceresearch.com/
Logo: https://mma.prnewswire.com/media/2562161/Credence_Research_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/cell-and-gene-therapy-manufacturing-market-to-reach-usd-146-2-billion-by-2032-amid-rising-demand-for-personalized-therapies-viral-vector-capacity-and-automated-bioprocessing–credence-research-302708581.html
Tengo varias preguntas sobre esto a ver si me podiais aclarar:
-¿Puedo hacer un ingreso regular de 800 euros y me cobran 0euos de comisiones y mto.?
-¿Puedo sacar el dinero cuando quiera?,¿todo ó tengo entendido que hay que mantener un mínimo de 100 euros los 30 meses?
-No necesito pero me obligan a sacar una tarjeta de débito que me cuesta 11 euros el primer año y 22 euros la renovación, también otra de credito que me cuesta 0 euros el primer año y 35 euros la renovación.
¿Hay que mantenerlas 13 meses?
¿Puedo cancelar alguna de ellas desde el principio?
¿Puedo cancelar alguna de ellas antes de la renovación?
¿Hay alguna tarjeta de credito más barata?
Aparte de la cuenta nómina he visto que también que para que te den la tv también se puede sacar una cuenta tarifa plana básica o personal, ¿sabeis algo de estas cuentas?¿que requisitos tienen?
Muchas gracias a todos por responder
Yo fui a informarme y te cuento. Únicamente admiten los ingresos regulares en el caso de que seas autónomo. Te abren una cuenta Tarifa Plana Cero que está exenta de comisiones y presenta alguna ventaja más. Sobre dejar un mínimo de saldo en la cuenta no es necesario, pero sí te obligan a mantener varias tarjetas durante los 30 meses con un coste aproximado de 100 euros anuales.
hola buenas!
me llamo javi y estoy dudando de que banco, me puede dar mas beficios, sin sorpresas por domiciliar la nomina, ya que llevo años en la caixa y no me da nada ningun beneficio. es mas me rechazan los prestamos que solicito, ni siquiera una targeta de credito, por alegan de que siempre esta a cero la cuenta, yo cuando cobro la nomina dejo el dinero para los pagos, y saco el resto, pues no me fio, de que un dia me quede sin dinero, ya que esta todo muy mal, corre riesgo mi dinero o mis ahorros en el banco?? muchas gracias y un cordial saludo.
javi
NO TE EXTRAÑE QUE NO TE DEN LOS PTMOS, PORQUE LO QUE VEN ES QUE NO TIENES CAPACIDAD DE AHORRO PORQUE SIEMPRE DEJAS LA CTA. EN MINIMOS, ASI NINGUN BANCO TE LO VA A CONCEDER. TAMBIEN ES VERDAD QUE LA CAIXA, COMO TANTAS OTRAS CAJAS, TIENE EL PUÑO CERRADO PARA LOS RIESGOS, PARA REMONTAR. NO TE PREOCUPES, QUE POR UNA NOMINA NO CREO QUE NINGUN BANCO SE COJA LAS MANOS. LOS QUE SE TIENEN QUE PREOCUPAR SON LOS QUE TIENEN DÉPÓSITOS Y FONDOS EN BANCOS DE DUDOSA ACTIVIDAD. LA GENTE SE PIENSA QUE PORQUE LES DEN UN 7% YA ES UN GRAN BANCO Y SE EQUIVOCAN. LO QUE LES PASA ES QUE EL BANCO DE ESPAÑA LES PRESTA EL DINERO MAS CARO Y POR ESO OPTAN POR CONSEGUIRLO EN EL MERCADO MONETARIO, Y SI EL BANCO DE ESPAÑA NO SE FIA DE ELLOS, VA Y SE FIA LA GENTE. QUE LOS BANCOS NOES LA ADMON PUBLICA, ABRAN OS OJOS.
Hola , cuando vallais al banco queos dejen lo que hay que pagar de irpf y de iva sobre el valor de la tele ya que en la mayoria de bancos esto no lo dicen y luego llagan las sorpresas .A mi ya me ha pasado con la promoción del portatil y nunca me hablaros de esto . Cuidado
Yo he estado calculando y la tele entre unas cosas y otras te sale sobre unos 250euros que tampoco regalan tanto .Hay oficinas en las que han dado la occión de poner un dinero a plazo fijo a 12meses de 9300euros o 6800euros a 18 meses.
No es ningún chollo. Te obligan a contratar dos tarjetas de crédito que tienes que pagar porque las tienes que mantener 13 meses por lo menos y además llevan unos costes desproporcionados si las utilizas. En total, no usando las tarjetas y anulándolas una vez cumplidos los 13 meses puedes ahorrar unos 38 euros con respecto al precio de ese televisor en una gran superficie. Y además luego vendrá que te cobran para hacienda la retención correspondiente, por lo que probablemente incluso en las mejores condiciones te cueste más que si ahorras un poco y lña compras directamente.
Creó que teneis toda la razón, que aqui no te regalan nada, ya que a mí me paso con unas sartenes que regalaban el banco bilbao, que al final entre el irpf y el descuento de Hacienda, al final me salieron caras, así es que no os tomen el pelo, que al final siempre esta la letra pequeña que es la que nos joroba, por no decir otra cosa.
Yo saque el portatil y ahora me he sacado la TV LCD 32. Estas promos no hay que declararlas. No es obligado domiciliar nomina. Si, meter en la cuenta 800€ todos los meses en un margen de 10 dias. Cero matacero, pero cero,cero, cero de gastos de mantenimiento, ni por recibos, ni por el correo a casa, ni por transfer. Las tarjets gratis el 1er año. Resto fuera. Dadas de baja Menos la de debito. Banesto no pierde nada, ganar, gana clientes que es el proposito de esta promo. Precio de portatil y tv 32 en mercao unos 900€ los 2. En banest 197€. Los hay mejores, nos ha jodio! portatiles a 1200€, TV LCD 32 a 1000€. Señores, son lentejas. Relacion calida-precio-promo es cojonud…….Un saludit a los viandantes.
hola , no se si llegara mi comentario pero os voi a esplicar. esto es el cuento de la abuela. mira yo tengo el portatil. y he cogio tab la tele, pero sabeis ke?, me ha pasado de todo. os esplico. primero me cobran 74 euros y 25 euros de unas tarjetas que yo no las he visto aparecer por mi casa , me cabreo con el banco. llamo y pido esplicaciones. me dicen que van en la promocion, nunca jamas nadie me informo de las tarjetas, no me devuelven el dinero. me cabreo y me dicen que llame aun numero de tefono para darlas de baja, se pasan los dias, intentamos darlas de baja. largas y larga, que si este numero de tefono que si el otro bla bla bla. conseguimos hablar y nos dicen que tenemos que cambiar el contrato a tarifa plana o no se ke historias, llamando al banco se pasan los dias, largas y largas. me cabreo y estoi por suspender todo, me dicen que si lo quiero cambiar y dar de baja las tarjetas que nunca he tenido. tengo que pagar comisiones cada seis meses de doce y pico euros, y que si no quiero que me cobren comisiones tengo que ir todos los meses al banco a hacerlo yo, ufffffffffff.aun hay mas. me dan de baja y me hacen la tarifa plana, se equivocan un monton de veces. me hacen pasar muchos cabreos.y al final cuando llego a casa me han cobrado 25, 50 euros. y llamo por telefono y se lo digo , me dicen claro por dar de baja la otra cuenta , la madre que los pario. ladrones. o sea os digo que la tele no sale regalada, se la cobran y muy bien cobrada , nadie da nada por nada. en cuento termine de pagar lo que debo quito todas las cuentas del banesto.espero que alguien me lea y que me conteste gracias .
Banesto ha jodido a mi marido y a un amigo tambien. Para mi, despues de Banco de Andalucía son los peores. Y quieran creerlo o no ni la television ni el portátil te lo regalan.. como no cumplas cualquiera de las reglas te sancionan con 300 y pico de euros.. porque nos hemos mudado de casa y los recibos domiciados se cortaron «temporalmente» la sancion fue de mas de 300 euros.. y el cabreo q te llevas cuando ves lo q te han descontado y luego para ir a reclamarlos.. y como te tratan !! en fin.. espero que Banesto sea lo primero en undirse en el fin del mundo!!
CHOLLO!!!!!!!!!JAJAJAJAJA…….NO ES NINGUN CHOLLO!!!!!!! te cobran 100 € de gastos de manipulacion, mas 150 € en tarjetas durante 2 años, mas 6 € mensuales de mantenimiento de cuenta durante 30 meses, total que pagas 630 Euros por un ordenador o una TV que su valor seguro que no llega a 500 €. Y encima si vas a cancelar la cuenta cuando cumples los 30 meses requeridos te hacen esperar dos horas para decirte que no tienen linea de telefono para dar de baja la cuenta, cosa que no para nunca cuando vas a contratarlo. Y del trato que dispensan….., es el mismo que si vas con un fajo de billetes de 500 € por los CO-JONES
Banesto «premia», menuda falacia…
No hay ningún banco que premie a nadie.
BANESTO NECESITA NUESTRAS NÓMINAS, Y EN CUANTO VAS UN POCO JUSTO, COMO BUENOS JUDÍOS Y ÁVAROS QUE SON, TE ACOSAN Y MACHACAN, Y TE SACAN HASTA LAS ENTRAÑAS EN COMISIONES.
DESPUÉS EL ESTADO APOYA A LOS BANCOS, CON LA EXCUSA DE QUE SI CAEN LOS BANCOS CAEMOS TODOS. LOS BANCOS NECESITAN UN BOICOT DE VEZ EN CUANDO, PARA QUE NO NOS RESTREGUEN POR LA CARA SUS BENEFICIOS.
POR CIERTO, LO QUE MÁS FASTIDIA A UN BANCO ES UNA RECLAMACIÓN EN LA OFICINA DEL CONSUMIDOR Y OTRA AL BANCO DE ESPAÑA.
ES POR DAR PISTAS…